A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD

Von Willebrand Diseases Clinical Trial

— EMPOWER  

Official title:

A Multi-cEnter, Pilot, Crossover Trial of Prophylactic Wilate coMpared to PlacebO for Heavy Menstrual Bleeding in Patients With Von WillEbRand Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06205095
• Other study ID #: 2.2
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 2024
• Est. completion date: September 2026

Study information

• Verified date: May 2024
• Source: Unity Health Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial

Description:

The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial. For the first treatment period, patients will be randomized to receive either plasma derived von Willebrand factor:Factor VIII (pdVWF:FVIII) concentrate (plus standard of care) or placebo (plus standard of care) for VWD-associated heavy menstrual bleeding for 4 cycles, crossing over to the comparator treatment during the second treatment period. The first treatment period will be followed by a 1 cycle washout period when no study-based treatment will be delivered. The main purpose of the pilot will be to evaluate viability and feasibility of the trial design, as well as to explore assay sensitivity to inform determination of the primary efficacy outcome for the definitive randomized trial which will evaluate the effect of prophylaxis with pdVWF:FVIII concentrate compared with placebo on HMB in women with VWD. A secondary objective is to conduct a preliminary assessment of the effect on clinical outcomes of 2-3 doses of prophylaxis with pdVWF:FVIII concentrate when provided on the first 4 days of menstruation compared with placebo.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: September 2026
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient capable of providing informed consent;

2. Female patients with HMB over the age of 18 years, for whom prophylactic treatment with Wilate® is deemed clinically appropriate according to the medical discretion (based on their expert opinion given consideration of the patient's bleeding history and responsiveness to treatment) of the treating hemostasis-focused physician practicing at a Hemophilia Treatment Center;

3. Modified PBAC score > 100 at screening;

4. Patients with a diagnosis of inherited von Willebrand disease (any type);

5. Stable treatment for HMB and iron deficiency anemia for 3 cycles before entering the study and anticipated to remain unchanged for the duration of the study;

6. Patients willing to have an infusion administered by a nurse over the course of the study period;

7. Patients who agree to use only the feminine hygiene products supplied by the sponsor.

Exclusion Criteria:

1. Diagnosed with any other known bleeding disorder;

2. Pregnancy or plans to become pregnant within the duration of the study;

3. Breastfeeding or plans to breastfeed within the duration of the study;

4. Known hypersensitivity reactions to human plasma-derived products or any ingredient in the formulation;

5. Known antibodies to VWF or FVIII;

6. Severe liver disease;

7. Anticipated initiation of the following: oral, transdermal, injectable, and vaginal ring hormonal contraceptives; GnRH analogues; or a hormonal intrauterine device (IUD) within the study period;

8. Anticipated elective procedure that is expected to require intensive treatment with VWF or FVIII for >10 days during the study period;

9. Patients with >2 risk factors for VTE (risk factors are determined at discretion of treating physician) or recent history of thrombosis (i.e. within the last year).

10. Patient concurrently receiving desmopressin (desmopressin cannot be taken concurrently with Wilate®, except for in the context of escalation treatment for excessive bleeding).

11. Anticipated initiation of any new therapies for the treatment of heavy menstrual bleeding 3 weeks prior to enrollment

Related Conditions & MeSH terms

• Menorrhagia
• Von Willebrand Diseases

Intervention

Drug:
• Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.

Other:
• Placebo
Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Unity Health Toronto

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2	Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2	2 years
Primary	Proportion of participant drop-out at the end of treatment period 1 and 2	Proportion of participant drop-out at the end of treatment period 1 and 2	2 years
Primary	Proportion of participants with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2	Proportion of patients with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2	2 years
Primary	Number of participants enrolled in 2 years (i.e. ability to enroll at least 10 participants in 2 years)	Ability to enroll at least 10 participants in 2 years	2 years
Primary	Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2	Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2	2 years
Secondary	Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period	Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	The proportion of patients who use of rescue therapy at the end of each treatment period	The proportion of patients who use of rescue therapy (i.e. more than two days of oral tranexamic acid use, additional treatment with Wilate®, additional hormonal therapy for HMB, urgent/emergent gynecological surgery for HMB, treatment with intravenous iron, red blood cell transfusion, or hospital admission for HMB) at the end of each treatment period	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles	Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles	Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Number of days of oral tranexamic acid use	Number of days of oral tranexamic acid use	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Number of days of Wilate® treatment received	Number of days of Wilate® treatment received	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Duration of menstruation (measured in days)	Duration of menstruation (measured in days)	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition	Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Clinically relevant non-major bleed	Clinically relevant non-major bleed	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Hemoglobin levels (g/L)	Hemoglobin levels (g/L)	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Ferritin levels (mcg/L)	Ferritin levels (mcg/L)	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Use of additional hormonal therapy for heavy menstrual bleeding	Use of additional hormonal therapy for heavy menstrual bleeding	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding	Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Fatigue scores (as measured by the FACIT fatigue scale)	Fatigue scores (as measured by the FACIT fatigue scale)	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Short Form-12 Scores	Short Form-12 Scores	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Scores on the individual components of the Short Form-12	Scores on the individual components of the Short Form-12	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)	Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)	Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Number of hypersensitivity infusion reactions	Number of hypersensitivity infusion reactions	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);	Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Proportion of participants who development of VWF inhibitors	Proportion of participants who development of VWF inhibitors	At the end of 8 menstrual cycles (approximately 10 days)
Secondary	Number of adverse events	Number of adverse events	8 cycles